en · de · es · fr · pt
peptide-index.peptides9002.com › Topic › Selank Background And Peptide Chemistry — Worked Examples

Selank Background And Peptide Chemistry — Worked Examples

By Editorial Desk · published 2025-11-24 · last reviewed 2025-12-29 · Topic

tuftsin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-12-29. Numbers and descriptions here follow the published literature rather than marketing material.

Selank Background and Peptide Chemistry

Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.

Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.

Analytical Methods and Stability

Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.

Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.

Selank at a glance

PropertyValueNotes
Molecular formulaC33H57N11O9Derived from the seven-residue sequence
Molecular weightAbout 751.9 g/molAverage mass; the monoisotopic value is slightly lower
Residue countSeven amino acidsThr-Lys-Pro-Arg-Pro-Gly-Pro
Parent compoundTuftsin (Thr-Lys-Pro-Arg)Selank extends tuftsin at the C-terminus
Compound classSynthetic short peptideStudied in a research setting; not a licensed drug in most markets

Mechanism and Evidence Status

Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.

Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Related pages on this site

Mechanism and Evidence Base

Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.

Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.

Background and Molecular Identity

Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.

Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.

Peptide Identity and Structure

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

Background from the literature

== Qualifying == Teams that were not members of either the Premier League or English Football League competed in the qualifying rounds to secure one of 32 available places in the first round. On 6 August 2022, in an extra preliminary round match against Fleet Town, Newport (IOW) teenager Finn Smith became the youngest ever FA Cup goalscorer, a day after his 16th birthday. The fourth and final qualifying round was played on the weekend beginning 15 October. The winners from the fourth qualifying round were Oldham Athletic, AFC Fylde, King's Lynn Town, York City, South Shields, Curzon Ashton, Wrexham, Solihull Moors, Gateshead, Chesterfield, Alvechurch, Buxton, Coalville Town, FC Halifax Town, Torquay United, Maidenhead United, Hereford, Taunton Town, Eastleigh, Woking, Dagenham & Redbridge, Ebbsfleet United, Chippenham Town, Weymouth, Oxford City, Bracknell Town, Needham Market, Chelmsford City, Boreham Wood, Merthyr Town, Farnborough and Barnet. Needham Market was the only club in this season's tournament appearing in the competition proper for the first time, although reconstituted sides Merthyr Town and Farnborough were featuring at this stage for the first time in their own right following the liquidation of Merthyr Tydfil FC (in 2010) and Farnborough Town (in 2007). Of the others, Weymouth had last appeared in the first round in 2007-08, Coalville Town had last done so in 2004–05, Bracknell Town had last done so in 2000-01 and Alvechurch had last done so in 1973-74.

=== Contrast agents, bioimaging === Functionalized and surfactant dispersed graphene solutions have been designed as blood pool MRI contrast agents. Further, iodine and manganese incorporating graphene nanoparticles have served as multimodal MRI-computerized tomograph (CT) contrast agents. Graphene micro- and nano-particles have served as contrast agents for photoacoustic and thermoacoustic tomography. Graphene has also been reported to be efficiently taking up cancerous cells thereby enabling the design of drug delivery agents for cancer therapy. Graphene nanoparticles of various morphologies such as graphene nanoribbons, graphene nanoplatelets and graphene nanoonions are non-toxic at low concentrations and do not alter stem cell differentiation suggesting that they may be safe to use for biomedical applications.

The Peptide Transporter Carbon Starvation (CstA) Family (TC# 2.A.114) is a member of the APC superfamily and consists of proteins from bacteria and archaea. These proteins are of various sizes and topologies. For example, CstA of E. coli has 701 aas with 18 putative TMSs. It has a long N-terminal CstA domain and a short C-terminal DUF4161 domain. This protein is encoded by a carbon starvation inducible gene, cstA, that is under cyclic AMP-CRP control. Circumstantial evidence suggested that it may be a peptide transporter. A Campylobacter jejuni homologue has been shown to transport di- and tripeptides (see TC# 2.A.114.1.5). Proteins currently known to belong to the CstA family are listed in the Transporter Classification Database. As of early 2016, there is no crystal structural data available for members of the CstA family on RCSB.

Sources: en.wikipedia.org

Reference notes

==== Film works and graphic novel ==== Antonov worked on the 2006 film Renaissance directed by Christian Volkman. He then wrote and illustrated the graphic novel The Colony: A Structure Celebrating the Triumphs of Technology, published in 2010. Antonov was also a co-writer and production designer of the 2011 French sci-fi film The Prodigies.

==== Hormones and steroids ==== There is theoretical concern, and animal evidence, that environmental hormones and chemicals may affect aspects of prenatal or postnatal sexual development in humans. Bisphenol A (BPA) is a chemical used to make plastics, and is frequently used to make baby bottles, water bottles, sports equipment, medical devices, and as a coating in food and beverage cans. Scientists are concerned about BPA's behavioral effects on fetuses, infants, and children at current exposure levels because it can affect the prostate gland, mammary gland, and lead to early puberty in females. BPA mimics and interferes with the action of estrogen—an important reproduction and development regulator. It leaches out of plastic into liquids and foods, and the Centers for Disease Control and Prevention (CDC) found measurable amounts of BPA in the bodies of more than 90 percent of the U.S. population studied. The highest estimated daily intakes of BPA occur in infants and children. Many plastic baby bottles contain BPA, and BPA is more likely to leach out of plastic when its temperature is increased, as when one warms a baby bottle or warms up food in the microwave.

Colonial administration records (migrated archives): Malaya at The National Archives (Pg. 52) The UK Statute Law Database: Federation of Malaya Independence Act 1957 (c. 60) United Nations Treaty Collection: No.10760: Agreement relating to Malaysia FEDERATION OF MALAYA AGREEMENT OF 5 AUGUST 1957 Media related to Federation of Malaya at Wikimedia Commons

Sources: en.wikipedia.org

Notes from published material

=== First Trump administration === Sanders criticized President Trump for appointing multiple billionaires to his cabinet. He criticized Trump's rolling back President Obama's Clean Power Plan, noting the scientifically reported effect on climate change of human activity and citing Trump's calling those reports a hoax. He called for caution on the Syrian Civil War, saying, "It's easier to get into a war than out of one." In 2017, he promised to defeat "Trump and Trumpism and the Republican right-wing ideology". Sanders gave an online reply to Trump's January 2018 State of the Union address in which he called Trump "compulsively dishonest" and criticized him for initiating "a looming immigration crisis" by ending the Deferred Action for Childhood Arrivals program. He voiced concern about Trump's failure to mention the finding that Russia had interfered in the 2016 election and "will likely interfere in the 2018 midterms we will be holding ... Unless you have a very special relationship with Mr. Putin". On January 6, 2021, Trump supporters attacked the United States Capitol. Sanders commented: "[Trump] has made it clear that he will do anything to remain in power – including insurrection and inciting violence [and he] will go down in history as the worst and most dangerous president in history." Sanders voted to convict Trump on both articles of his first impeachment trial in 2020 (for pressuring a foreign leader to investigate Joe Biden), and again on the sole article of his second impeachment trial in 2021 (for inciting the Capitol attack).

== Research in immunology == Its function as a detergent and isolating agent for membrane proteins also suits it for production of outer membrane protein (OMP) vaccines such as MenB, a Norwegian vaccine developed in the early 1990s. The MeNZB vaccine was produced using the same method. Deoxycholic acid binds and activates the membrane enzyme NAPE-PLD, which catalyzes the release of the endogenous cannabinoid anandamide and other N-acylethanolamines. These bioactive signaling molecules play important roles in several physiological pathways including stress and pain response, appetite, and lifespan. Some publications point towards the effect of deoxycholic acid as an immunostimulant of the innate immune system, activating its main actors, the macrophages. According to these publications, a sufficient amount of deoxycholic acid in the human body would correspond with a good immune reaction of the non-specific immune system. Clinical studies conducted in the 1970s and 1980s confirm the expectation that deoxycholic acid is involved in the natural healing processes of local inflammations, different types of herpes, and possibly cancer.

=== Bibliography === Wiseman A (1993). "Designer enzyme and cell applications in industry and in environmental monitoring". J Chem Technol Biotechnol. 56 (1): 3–13. Bibcode:1993JCTB...56....3W. doi:10.1002/jctb.280560103. PMID 7763363. Diekmann S, Weston J, Anders E, et al. (April 2002). "Metal-mediated reactions modeled after nature". J. Biotechnol. 90 (2): 73–94. doi:10.1016/s1389-0352(01)00067-8. PMID 12069195.

==== Vitatron ==== Vitatron is a Netherlands-based European subsidiary of Medtronic. It is focused on development and manufacturing of cardiac pacing technology. Once an independently operating Dutch medical company, it was acquired by Medtronic in 1986. Vitatron pacemakers are interrogated and programmed by Medtronic Carelink Model 2090 Programmer for Medtronic and Vitatron Devices, using a separate interface.

Sources: en.wikipedia.org

Frequently asked questions

What is selank?

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.

How does selank differ from tuftsin?

Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.

Is the mechanism of action established?

No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.

How is selank identified in a laboratory?

Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.

Network